A · Agilent Technologies, Inc.

Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for 9:20 EDT on Wednesday, June 3, 2026, in New York City. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com . To receive the latest Agilent news, subscribe to the

Agilent Technologies Inc. (NYSE: A) today announced the appointment of Michael Buckner as chief legal officer, effective today. Buckner brings nearly three decades of experience as a senior global legal executive, with a proven track record of building and leading high-performing teams and deep expertise in complex transactions and regulatory environments. “We are thrilled to welcome Michael to the Agilent team,” said Padraig McDonnell, Agilent president and CEO. “His experience leading global legal organizations, combined with his expertise across governance, compliance and regulatory matters, will play a key role as we continue to advance our strategy and deliver for our customers and stakeholders worldwide.” Buckner joins Agilent from Danaher Corp., where he served as vice president, deputy general counsel, and chief M&A counsel. In this role, he led legal strategy for mergers and acquisitions, antitrust, intellectual property transactions, and debt securities, while overseeing

​Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2026 after the stock market closes on Wednesday, May 27. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s Investor Relations website. A recording of the call will also be available on the website for 90 days. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is

Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for more integrated approaches across the cancer research continuum. Among the technologies featured is the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation series of cell imaging and multimode microplate readers. Cytation 9 is designed to support advanced live‑cell and endpoint assays by combining automated microscopy with conventional microplate reading in a single system, supporting a range of cell‑based research applications. In addition, Agilent will provide an early preview of the upcoming

Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic research through high‑content screening. Designed for researchers running both cell-based and biochemical assays, Cytation 9 brings expanded imaging capabilities along with advanced hybrid microplate detection technologies. Key features include inverted fluorescence microscopy, upright imaging, and a multimode microplate reader module in a single instrument, helping laboratories streamline workflows while maintaining flexibility across diverse applications. Since first introduced in 2013, the BioTek Cytation portfolio has served as an

Test enables identification of patients whose tumors express PD-L1 for potential treatment with KEYTRUDA® (pembrolizumab) 1, 2 Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indicated to identify patients with esophageal or GEJ carcinoma whose tumors express PD-L1 (Combined Positive Score (CPS) ≥ 1) who may be eligible for treatment with KEYTRUDA. This approval marks the eighth FDA approved companion diagnostic indication currently available for PD-L1 IHC 22C3 pharmDx, Code SK006, for use with KEYTRUDA. “With the expanded FDA approval of PD-L1 IHC 22C3 pharmDx in esophageal or GEJ

Expanded PD‑L1 indication and end‑to‑end digital pathology workflows support modern pathology practice Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a foundation for scalable, automation‑ready pathology laboratories. At USCAP 2026, Agilent will feature its continued expansion in oncology diagnostics, including a new PD‑L1 indication for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), reinforcing Agilent’s commitment to supporting biomarker‑driven precision oncology. This addition builds on Agilent’s established PD‑L1 portfolio and supports laboratories as

Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing solutions. Agilent Advanced Therapeutics’ CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development. The integrated platform provides customers streamlined access to end-to-end development and manufacturing services through a single partner — from discovery and process development through clinical- and commercial-scale manufacturing. “The Agilent Advanced Therapeutics solution strengthens our ability to support our customers and

Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit revenue and profit growth since 2021 Expected to be accretive to Agilent’s top-line growth rate, margin profile and non-instrument revenue mix in Year 1 Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions designed to support improved patient health outcomes across oncology and broader clinical pathology. With more than 300 specialized antibodies and a proven R&D capability, Biocare

Delivers solid Q1 results, raises FY26 reported revenue outlook and increases non-GAAP EPS(3) guidance while confirming core - revenue growth(1) and margin expansion First-quarter fiscal year 2026 Revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% on a core (1) basis compared with the first quarter of 2025. GAAP net income of $305 million; earnings per share (EPS) of $1.07, a decline of 4% from the first quarter of 2025. Non-GAAP (2) net income of $386 million; non-GAAP EPS (3) of $1.36, growing 4% from the first quarter of 2025. Fiscal year 2026 and second-quarter outlook Fiscal year 2026 revenue is expected in the range of $7.3 billion to $7.5 billion, representing a range of up 5.5% to 7.5% reported and up 4% to 6% core (1) . Non-GAAP EPS (3) is expected in the range of $5.90 to $6.04. Fiscal second-quarter 2026 revenue guidance is expected in the range of $1.79 billion to $1.82 billion, growth of approximately 7% to